TB-500: legal
This page summarises TB-500's status in the places checked; it is not legal advice, and it does not cover every country or state.
United States
TB-500 does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. The FDA's page on bulk drug substances that may present significant safety risks lists “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” under “Bulk drug substances nominated but withdrawn”, and explains: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators”.[2] Its safety text stays on the page and includes: “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.”[2]
The Department of Health and Human Services then put TB-500 on its “503A Interim Access List”, the sequence given as “Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH”.[3] It records that “TB-500 was in Category 2 from September 29, 2023, until April 22, 2026”.[3] Under the policy, HHS says that “HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding it, on its conditions, and for TB-500 only in subcutaneous or “intramuscular injectable dosage forms”.[3] That is a policy about pharmacy compounding on prescription, not about research vials sold online. See the regulated peptide market for the policy in full. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.
Sport
The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, lists “Thymosin-ß4 and its derivatives e.g. TB-500” among growth factors and growth factor modulators.[4] That section is headed “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)”, so it applies out of competition as well, and states: “All prohibited substances in this class are non-Specified Substances.”[4] Non-specified means the list treats a positive test as more likely to be deliberate.
References
- 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026), Wayback capture of 19 October 2026 — US Food and Drug Administration
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B, Wayback capture of 15 November 2026 — US Department of Health and Human Services, Office of the Secretary
- World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency
Comments
Sign in to join the conversation.
No comments yet.